Grifols reported EUR2.37B in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Alaunos Therapeutics USD 864K 269K Jun/2026
Arca Biopharma USD 31.78M 8.81M Sep/2026
aTyr Pharma USD 16.46M 5.07M Sep/2026
Bio Path USD 9.15M 468K Mar/2026
Brainstorm Cell Therapeutics USD 12.38M 621K Jun/2026
Capricor Therapeutics USD 29.9M 3.07M Sep/2026
Cara Therapeutics USD 8.08M 3.18M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Grifols EUR 2.37B 156.97M Dec/2025
Immunic USD 31.55M 290K Sep/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
TherapeuticsMD USD 5.82M 655K Jun/2024